Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05794100 · ClinicalTrials.gov registry record · NA

Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance

A NA study of Tolerance and Healthy Population, sponsored by Mondelēz International.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05794100 is a NA study of Tolerance and Healthy Population that has completed, run by Mondelēz International. The registered enrollment target is 60 participants, above the 47-participant average among 7 other Tolerance trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05794100, a NA study of Tolerance and Healthy Population, has completed, sponsored by Mondelēz International.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study is a randomized, double-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of 3 sugar replacers mixes at 3 different doses. The investigators will also try to understand the factors that could explain the presence or absence of symptoms

Interventions

  • OTHER Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator

Study Locations (1)

Illinois

  • Biofortis Innovation Services - Addison

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-10-11
Est. Completion 2022-07-30
Phase NA

Sponsor

Mondelēz International

7 total trials

What the Registry Record Tells You About NCT05794100

The ClinicalTrials.gov registry entry for NCT05794100 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 47-participant average among 7 other Tolerance trials with a reported enrollment target (28% higher). The listed sponsor is Mondelēz International, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tolerance appearing as the primary indexed condition, and to 1 intervention - of which Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator is the first listed.

NCT05794100 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05794100 about?

NCT05794100 is a clinical study titled "Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance". This study is a randomized, double-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of 3 sugar replacers mixes at 3 different doses. The investigators will also try to understand the factors that could explain the presence or absence of symptoms

What is the current status of trial NCT05794100?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2021-10-11. Estimated completion is 2022-07-30.

What conditions does trial NCT05794100 study?

This clinical trial studies the following conditions: Tolerance, Healthy Population.

What interventions are being tested in trial NCT05794100?

The interventions under investigation include: Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator (OTHER).

Who is sponsoring clinical trial NCT05794100?

This trial is sponsored by Mondelēz International, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05794100 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tolerance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.